Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Pfizer

Next Previous
Drug Profile

Trastuzumab biosimilar - Pfizer

Alternative Names: PF-05280014; PF-5280014; Trastuzumab - Pfizer; TRAZIMERA

Latest Information Update: 15 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 27 Jun 2020 Pfizer completes a phase-III trial in HER2-positive-breast-cancer (First-line therapy, Metastatic disease, Combination therapy) in Hungary, the Czech Republic, Japan, Portugal, Poland, Romania, Spain, South Korea, Philippines, Ukraine, Russia, Greece, Chile, South Africa, USA, Argentina, Brazil, India, Latvia, Mexico, Peru, Serbia, Slovakia, Thailand, Turkey (NCT01989676)
  • 23 Jan 2020 Pfizer plans to launch trastuzumab biosimilar in the US for the treatment in Breast cancer and Gastric cancer on 15th February, 2020
  • 10 Dec 2019 Updated safety and efficacy data from the phase III REFLECTIONS B327-02 trial in HER2-positive-breast-cancer presented at the 42nd Annual San Antonio Breast Cancer Symposium (SABCS-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top